MedTrace Logo

Lofexidine for Adults Undergoing Lumbar Spine Surgery

NCT04126083 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-02-23

Study results available
· View outcomes & findings →

Summary

The primary objective is to investigate the effects of lofexidine in adults undergoing opioid tapering prior to elective lumbar spine surgery.

Conditions

  • Opioid Withdrawal

Interventions

DRUG

Lofexidine Oral Tablet

lofexidine 0.54 mg 4 times daily

Sponsors & Collaborators

  • USWM, LLC (dba US WorldMeds)

    collaborator INDUSTRY

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • William M Hooten, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2021-04-15
Completion
2021-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04126083 on ClinicalTrials.gov